Document 0495
 DOCN  M9590495
 TI    Hepatitis B vaccination in infants of mothers infected with human
       immunodeficiency virus.
 DT    9509
 AU    Arrazola MP; de Juanes JR; Ramos JT; Aragon AJ; Garcia de Codes A;
       Preventive Medicine Service, University Hospital 12 de Octubre,; Madrid,
       Spain.
 SO    J Med Virol. 1995 Mar;45(3):339-41. Unique Identifier : AIDSLINE
       MED/95294564
 AB    A study was conducted to investigate the immunogenicity of a recombinant
       DNA hepatitis B vaccine in neonates and children of HIV-infected women.
       Immunization against hepatitis B consisted of three 10 micrograms doses
       of the vaccine administered on a 0-, 1- and 6-month schedule. The
       children were followed up for an average of 11 months. Of the 118
       HIV-positive neonates who participated in the study, 95 lost their HIV
       antibodies during the follow-up period. Most (94.2%) of the latter who
       completed the study responded to the vaccine. Of the 23 who remained
       HIV-positive, 17 completed the study and 7 produced hepatitis B
       antibodies.
 DE    Adult  Child  Child, Preschool  Disease Transmission, Vertical  Female
       Hepatitis B/COMPLICATIONS/IMMUNOLOGY/*PREVENTION & CONTROL  Hepatitis B
       Antibodies/BIOSYNTHESIS  Hepatitis B Vaccines/IMMUNOLOGY/*PHARMACOLOGY
       Human  HIV Infections/*COMPLICATIONS/IMMUNOLOGY/TRANSMISSION  HIV
       Seronegativity/IMMUNOLOGY  HIV Seropositivity/COMPLICATIONS/IMMUNOLOGY
       Infant  Infant, Newborn  Male  Pregnancy  Pregnancy Complications,
       Infectious/*IMMUNOLOGY  Vaccines, Synthetic/IMMUNOLOGY/*PHARMACOLOGY
       CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).